Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.54 |
| ▸ | CTSA | P10619 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824513 | 1.00 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL29841550 | 0.95 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL14254979 | 0.95 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL3655237 | 0.92 | MMP8 (0.54) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL27758476 | 0.91 | MMP8 (0.49) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL4162223 | 0.90 | MMP8 (0.48) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL22242513 | 0.88 | MMP8 (0.47) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL3655233 | 0.86 | KMT2A (0.47) | MMP8CTSAALDH1A1MAPTGAA | |
| SCHEMBL11189555 | 0.85 | ALDH1A1 (0.46) | MMP8CTSAALDH1A1MAPTHPGD | |
| SCHEMBL13523030 | 0.85 | MMP8 (0.45) | MMP8CTSAALDH1A1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4093738-B1 | MESOIONIC INSECTICIDES | FMC CORP (US) | 2024-03-06 | — | — | EP | disclosed |
| US-20230101273-A1 | MESOIONIC INSECTICIDES | FMC CORPORATION | 2023-03-30 | — | — | US | disclosed |
| EP-4093738-A1 | MESOIONIC INSECTICIDES | FMC CORPORATION (US) | 2022-11-30 | — | — | EP | disclosed |
| CN-115103843-A | Mesoionic insecticides | FMC公司 | 2022-09-23 | — | — | CN | disclosed |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| WO-2021151034-A1 | MESOIONIC INSECTICIDES | FMC CORPORATION (US) | 2021-07-29 | — | — | WO | disclosed |
| CN-107106526-B | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | 普罗米蒂克医药SMT有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, THE | 2007-01-11 | — | — | US | disclosed |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2006-10-26 | — | — | US | disclosed |
| US-7126001-B2 | Class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2006-10-24 | — | — | US | disclosed |
| CN-1238347-C | Heterocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2006-01-25 | — | — | CN | disclosed |
| EP-1231919-A4 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | SLOAN KETTERING INSTITUTEFOR C (US) | 2005-02-23 | — | — | EP | disclosed |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH | 2004-01-01 | — | — | US | disclosed |
| CN-1430612-A | Hete rocyclic derivatives | NIPPON SHINYAKU CO LTD (JP) | 2003-07-16 | — | — | CN | disclosed |
| US-6511990-B1 | Selectively inducing terminal differentiation of neoplastic cells and thereby inhibiting proliferation | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2003-01-28 | — | — | US | disclosed |
| EP-1231919-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | Sloan-Kettering Institute For Cancer Research (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001018171-A2 | NOVEL CLASS OF CYTODIFFERENTIATING AGENTS AND HISTONE DEACETYLASE INHIBITORS, AND METHODS OF USE THEREOF | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | MMP8 286/4885CTSA 254/4885ALDH1A1 129/4885 |
| US-20060241129-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | MMP8 1639/4885CTSA 144/4885ALDH1A1 367/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | MMP8 1012/4885CTSA 788/4885ALDH1A1 190/4885 |
| US-20070010669-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | MMP8 1639/4885CTSA 144/4885ALDH1A1 367/4885 |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | COL1A1, CCNH, COL2A1 | MMP8 286/4885CTSA 254/4885ALDH1A1 129/4885 |
| US-20230101273-A1 | MESOIONIC INSECTICIDES | CHRM1, DDT, CHRM2 | MMP8 4079/4885CTSA 2786/4885ALDH1A1 1013/4885 |
| US-20040002506-A1 | Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof | ACIN1, HDAC3, HDAC1 | MMP8 1401/4885CTSA 91/4885ALDH1A1 398/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | MMP8 1261/4885CTSA 1824/4885ALDH1A1 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.